The headline number and what it covers

For patients facing a focal cartilage defect and weighing up whether ChondroFiller is likely to help, published cohorts point to a meaningful answer: across studies with three to five years of follow-up, 70–85% of appropriately selected patients achieve lasting, clinically meaningful symptom relief.

The hip literature offers a concrete illustration. In a cohort of 26 patients treated for acetabular cartilage defects — followed for between 12 and 60 months — 17 of 21 evaluable patients reported good or excellent results at three to five years, sitting squarely within that broader range.

The phrase "appropriately selected" carries real weight, and the criteria that define it are examined in detail later in this article. At this stage, understanding the treatment pathway matters: ChondroFiller is a type I collagen scaffold placed under ultrasound guidance as an outpatient procedure. Once positioned, the scaffold gels in situ and recruits the patient's own progenitor cells — a process of acellular matrix-induced chondrogenesis. The outcome measures explored in the sections that follow — IKDC functional scores and MOCART structural MRI scores — map the clinical and radiological story of that repair process across two distinct timelines.

IKDC scores and what they mean in everyday terms

The International Knee Documentation Committee (IKDC) questionnaire gives each patient a score between 0 and 100 based on symptoms, function, and sport — the higher the number, the better the knee works in ordinary life.

Patients entering ChondroFiller treatment typically score around 48 on the IKDC. At that level, climbing stairs, walking for more than 20–30 minutes, or returning to recreational sport presents a real and daily obstacle. By the three-year mark, published cohorts place the average score at approximately 80 — a point at which most patients describe comfortable recreational activity without meaningful restriction.

That ~30-point rise matters because of where it sits relative to the Minimal Clinically Important Difference (MCID) — the smallest improvement a patient actually notices in daily life. For IKDC, the MCID is 16.7 points. Gains below that threshold can be statistically real yet remain imperceptible to the person living with the knee. The ~30-point improvement seen in ChondroFiller cohorts nearly doubles the MCID, placing it firmly in territory that patients notice.

Two independent datasets support this trajectory. The 2016 multicentre prospective trial recorded statistically significant IKDC improvements at 3, 6, and 12 months post-treatment (p<0.05). Simeonov et al. (2024), studying 17 patients with a mean age of 31, replicated the pattern — significant gains at each time point, with Lysholm scores improving in parallel. Importantly, the Simeonov data show no statistically significant difference between the six-month and twelve-month readings (p>0.05). This means most of the functional recovery happens within the first six months; the gain is then consolidated rather than extended further. Structurally, as the following section shows, the picture continues to evolve on MRI beyond that functional plateau.

MOCART scores and how the scaffold matures on MRI

MOCART — the Magnetic Resonance Observation of Cartilage Repair Tissue — is a scoring system applied to MRI scans of repaired cartilage. It grades the result out of 100 across several structural dimensions: how completely the defect has filled, how smoothly the repair tissue integrates with surrounding native cartilage, what the signal intensity looks like on MRI relative to healthy tissue, and how the underlying subchondral bone is holding up. A score approaching 100 reflects near-normal-appearing repair; lower scores indicate incomplete fill or poorer integration.

The figure most worth preparing patients for is the four-week reading. Across published data, MOCART scores at this point average approximately 65.3 — a number that can look underwhelming on paper. It does not signal failure. It reflects the scaffold-settlement phase: the collagen matrix has been delivered and is beginning to gel within the defect, but the host cells that will ultimately define the quality of repair have only just started migrating in. At four weeks, what the scan shows is a scaffold doing its early job, not a finished tissue.

The biological reason for this staged process is central to understanding the timeline. ChondroFiller works by acellular matrix-induced chondrogenesis — rather than delivering cells itself, the scaffold creates the structural environment that recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone. A 2025 ex vivo explant study demonstrated this directly: ChondroFiller produced a 2.4-fold increase in DNA content within the scaffold by day 14, confirming active cellular ingress within the first two weeks alone. Maturation then continues across subsequent months as those cells differentiate and deposit repair matrix.

By twelve months, MOCART scores consolidate to between 81.6 and 84.3 in cohort data, and independent studies consistently report one-year scores in the 70–87 range — a band classified as good to excellent structural repair. Crucially, structural maturation on MRI continues to advance beyond that twelve-month mark even after the functional IKDC gains have already plateaued. The two instruments are tracking different biological timelines: functional recovery tends to stabilise by around six months, while the tissue visible on MRI goes on refining itself. Neither score alone completes the picture, which is why serial imaging alongside patient-reported outcome measures remains the standard approach to monitoring progress.

When MOCART predicts outcome — and when it does not

A one-year MOCART 2.0 score carries real predictive weight — but with qualifications that shape how post-treatment scans should be read.

The positive case is well-evidenced. A 2025 study of 86 patients found that a MOCART 2.0 score of 60 or above at twelve months predicted meaningfully better patient-reported outcomes at final follow-up — higher IKDC, Lysholm, and KOOS scores, and lower osteoarthritis grades. The ROC-derived threshold sat between 56 and 61 points: patients above that line did significantly better than those below it.

A separate 2025 analysis — 111 patients and 188 MRI assessments — reached a different conclusion: no statistically significant overall correlation emerged between MOCART or MOCART 2.0 scores and change in patient-reported outcome measures.

Both findings can be simultaneously true. The first study identified a threshold effect — MOCART predicts outcomes when it crosses a clinically meaningful boundary, not because scores track smoothly with symptoms across the full range. The second measured correlation across the entire patient population, a broader statistical test that naturally dilutes threshold effects. Different study designs, different patient mixes, and different questions produced different answers from the same imaging tool.

The practical implication is clear. A MOCART score below 60 at one year is a signal for closer clinical review, not a verdict on the repair. A score above 60 adds structural reassurance — particularly when patient-reported symptoms are also improving. At review appointments, clinicians will weigh the scan alongside how the patient is actually functioning; neither source of information is sufficient alone.

Patient selection: who the scores apply to

Focal, contained defects within a joint that is otherwise healthy or near-healthy describe the patient profile to which published ChondroFiller outcomes most reliably apply. The distinction matters because ChondroFiller works by recruiting progenitor cells from the surrounding tissue; that recruitment depends on the local environment being capable of mounting a repair response. Where the joint is affected by widespread or advanced osteoarthritis, that environment is substantially compromised.

The hip cohort — 26 patients followed for 12 to 60 months — makes this explicit. Patients with Tönnis grade 2–3 osteoarthritis (a four-point scale running from 0, indicating no OA signs, to 3, indicating severe degeneration with significant joint-space narrowing) had poor outcomes. The 17 of 21 evaluable patients achieving good or excellent results at three to five years were those without advanced background joint disease. ChondroFiller is not indicated for generalised or advanced OA, and the published success rates do not represent patients in those categories.

Age and activity profile also feature in the literature. Simeonov et al. (2024) enrolled patients with a mean age of 31 — a younger, active cohort presenting with focal chondral lesions rather than degenerative wear patterns. Published evidence spans a broader age range, but that demographic remains the documented sweet spot.

Post-treatment loading adds a practical constraint with a mechanistic basis. A 2024 in vitro study found that ChondroFiller in its initial state could not reduce stress on opposing cartilage under early cyclic loading, owing to scaffold instability before stable defect fill is achieved. Weight-bearing restrictions in the early weeks are not precautionary routine — they reflect a documented window during which the forming repair tissue remains vulnerable to compression.

What the evidence gaps mean and the practical next step

The evidence base for ChondroFiller has real limits that anyone reading outcome scores deserves to understand plainly. No large, adequately powered randomised controlled trial has yet been published, and no head-to-head comparison with ACI or microfracture runs to equivalent follow-up lengths. Published cohorts are small — the knee studies cited here involve 13 to 86 participants — and selection criteria vary between them, which means the results cannot be extrapolated straightforwardly to every patient with a cartilage defect. Long-term durability data beyond five years remain sparse, particularly for knee applications.

What tempers that picture is consistency. Across study designs that differ in country, methodology, and patient age, IKDC gains are clinically significant, one-year MOCART scores fall in the good-to-excellent range, and the published complaint rate sits around 0.06%. Independent convergence across small cohorts is not the same as RCT-level proof — but it is a meaningful signal that the pattern holds when the right patient is treated.

That is the practical frame for these numbers. MOCART and IKDC scores describe what outcomes look like when the defect, the joint environment, and the patient's clinical history fit the published profile. Whether an individual's situation matches that profile is a clinical determination — one that warrants specialist assessment rather than a score comparison alone. London Cartilage Clinic's consultants assess candidacy for ChondroFiller as part of a structured outpatient evaluation on Harley Street.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] MOCART 2.0 score of 60 or greater measured at 1 year post-operatively predicts favourable clinical outcomes after surgical repair of tibiofemoral cartilage lesions. (2025). https://doi.org/10.1002/ksa.70086 https://doi.org/10.1002/ksa.70086
4. [4] Implantation of ChondroFiller Liquid as a scaffold material for chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] Correlation and Comparative Evaluation of MOCART and MOCART 2.0 for Assessing Cartilage Repair. (2025). https://doi.org/10.3390/medicina61040745 https://doi.org/10.3390/medicina61040745
6. [6] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
7. [7] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z